{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:24:51Z","timestamp":1778858691392,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.gtc.2010.08.009","type":"journal-article","created":{"date-parts":[[2010,10,18]],"date-time":"2010-10-18T05:45:27Z","timestamp":1287380727000},"page":"529-542","source":"Crossref","is-referenced-by-count":31,"title":["The Safety of Drugs Used in Acid-related Disorders and Functional Gastrointestinal Disorders"],"prefix":"10.1016","volume":"39","author":[{"given":"Neehar","family":"Parikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2010.08.009_bib1","unstructured":"Pantoprazole [package insert]. Philadelphia: Wyeth Pharmaceuticals; 2007."},{"key":"10.1016\/j.gtc.2010.08.009_bib2","unstructured":"Omeprazole [package insert]. Wilmington, DE: AstraZeneca LP; 2008."},{"key":"10.1016\/j.gtc.2010.08.009_bib3","unstructured":"Esomeprazole [package insert]. Wilmington, DE: AstraZeneca LP; 2008."},{"key":"10.1016\/j.gtc.2010.08.009_bib4","unstructured":"Lansoprazole [package insert]. Lake Forest, IL: Takeda Pharmaceuticals America Inc; 2009."},{"key":"10.1016\/j.gtc.2010.08.009_bib5","unstructured":"Rabeprazole [package insert]. Titusville, NJ: Eisai Co Ltd; 2009."},{"key":"10.1016\/j.gtc.2010.08.009_bib6","unstructured":"Dexlansoprazole [package insert]. Deerfield, IL: Takeda Pharmaceuticals America Inc; 2009."},{"issue":"8","key":"10.1016\/j.gtc.2010.08.009_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1046\/j.1365-2036.2003.01550.x","article-title":"A\u00a0summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole","volume":"17","author":"Labenz","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gtc.2010.08.009_bib8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2008.08.044","article-title":"American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease","volume":"135","author":"Kahrilas","year":"2008","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.gtc.2010.08.009_bib9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1345\/aph.1M051","article-title":"Drug-drug interaction between clopidogrel and the proton pump inhibitors","volume":"43","author":"Norgard","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"18","key":"10.1016\/j.gtc.2010.08.009_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.108.191087","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"118","author":"Bhatt","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.gtc.2010.08.009_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A\u00a0population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.gtc.2010.08.009_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"issue":"9694","key":"10.1016\/j.gtc.2010.08.009_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2010.08.009_bib14","author":"Wood"},{"issue":"1","key":"10.1016\/j.gtc.2010.08.009_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ajg.2009.638","article-title":"Proton pump inhibitor and clopidogrel interaction: fact or fiction?","volume":"105","author":"Laine","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.meegid.2009.06.005","article-title":"Clostridium difficile\u2013a continually evolving and problematic pathogen","volume":"9","author":"Dawson","year":"2009","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.gtc.2010.08.009_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/QCO.0b013e32818be71d","article-title":"Clostridium difficile: changing epidemiology and new treatment options","volume":"20","author":"Kuijper","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.gtc.2010.08.009_bib19","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gtc.2010.08.009_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/039463200802100109","article-title":"Omeprazole induces apoptosis in normal human polymorphonuclear leucocytes","volume":"21","author":"Capodicasa","year":"2008","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.gtc.2010.08.009_bib21","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/j.1572-0241.2008.01975.x","article-title":"Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients","volume":"103","author":"Aseeri","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2010.08.009_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2006.03015.x","article-title":"Proton pump inhibitor therapy is a risk factor for clostridium difficile-associated diarrhoea","volume":"24","author":"Yearsley","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.gtc.2010.08.009_bib23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.cgh.2007.09.010","article-title":"Use of acid-suppressing drugs and the risk of bacterial gastroenteritis","volume":"5","author":"Garcia Rodriguez","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.gtc.2010.08.009_bib24","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2010.08.009_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/gut.39.1.54","article-title":"Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study","volume":"39","author":"Thorens","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2010.08.009_bib26","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2010.08.009_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2010.08.009_bib28","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.2009.722","article-title":"Acid-suppressive medication use and the risk for hospital-acquired pneumonia","volume":"301","author":"Herzig","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.gtc.2010.08.009_bib29","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/gut.32.6.698","article-title":"Gastrin-histamine sequence in the regulation of gastric acid secretion","volume":"32","author":"Waldum","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2010.08.009_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2010.08.009_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","article-title":"Proton pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy","volume":"137","author":"Reimer","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.gtc.2010.08.009_bib32","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/ajg.2010.81","article-title":"Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial","volume":"105","author":"Niklasson","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.gtc.2010.08.009_bib33","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/ajg.2010.91","article-title":"Just how \u201cdifficult\u201d is it to withdraw PPI treatment?","volume":"105","author":"Howden","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib34","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.gtc.2010.08.009_bib35","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3177\/jnsv.44.869","article-title":"Effect of l-lactic acid on the absorption of calcium in gastrectomized rats","volume":"44","author":"Chonan","year":"1998","journal-title":"J\u00a0Nutr Sci Vitaminol (Tokyo)"},{"issue":"4","key":"10.1016\/j.gtc.2010.08.009_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2010.08.009_bib37","first-page":"414","article-title":"Proton pump inhibitors, H2 antagonists, and risk of hip fracture: a large, population-based study [abstract]","volume":"136","author":"Corley","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2010.08.009_bib38","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","article-title":"Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss","volume":"138","author":"Targownik","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2010.08.009_bib39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1592\/phco.28.8.951","article-title":"Proton pump inhibitor use and risk of hip fractures in patients without major risk factors","volume":"28","author":"Kaye","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.gtc.2010.08.009_bib40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1503\/cmaj.1031155","article-title":"Vitamin B12 (cobalamin) deficiency in elderly patients","volume":"171","author":"Andres","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.gtc.2010.08.009_bib41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jclinepi.2003.08.015","article-title":"A\u00a0case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults","volume":"57","author":"Valuck","year":"2004","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.gtc.2010.08.009_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2036.2008.03601.x","article-title":"Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals","volume":"27","author":"den Elzen","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2010.08.009_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-200001000-00006","article-title":"Vitamin B12 levels during prolonged treatment with proton pump inhibitors","volume":"30","author":"Howden","year":"2000","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.gtc.2010.08.009_bib44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2147\/ciia.2007.2.1.85","article-title":"Long-term management of GERD in the elderly with pantoprazole","volume":"2","author":"Calabrese","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.gtc.2010.08.009_bib45","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1007\/s11605-009-1015-3","article-title":"Proton pump inhibitors in the management of GERD","volume":"14","author":"Katz","year":"2010","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"5","key":"10.1016\/j.gtc.2010.08.009_bib46","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1440-1746.2007.04871.x","article-title":"Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine","volume":"22","author":"Miyamoto","year":"2007","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2010.08.009_bib47","first-page":"57","article-title":"Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors","volume":"19","author":"Lobera","year":"2009","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"issue":"4","key":"10.1016\/j.gtc.2010.08.009_bib48","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2036.2007.03407.x","article-title":"Systematic review: proton pump inhibitor-associated acute interstitial nephritis","volume":"26","author":"Sierra","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2010.08.009_bib49","first-page":"203","article-title":"Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature","volume":"16","author":"Demirkan","year":"2006","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.gtc.2010.08.009_bib50","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/ajg.2009.122","article-title":"The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis","volume":"104","author":"Gill","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2222.2008.03125.x","article-title":"First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study","volume":"39","author":"Dehlink","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.gtc.2010.08.009_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0149-2918(96)80177-9","article-title":"The tolerability and safety profile of famotidine","volume":"18","author":"Howden","year":"1996","journal-title":"Clin Ther"},{"key":"10.1016\/j.gtc.2010.08.009_bib53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2036.1991.tb00748.x","article-title":"Safety profile of long-term H2-antagonist therapy","volume":"5","author":"Lewis","year":"1991","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2010.08.009_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1993.tb00597.x","article-title":"Safety issues relating to long-term treatment with histamine H2-receptor antagonists","volume":"7","author":"Sabesin","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.gtc.2010.08.009_bib55","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1097\/00004836-199000000-00010","article-title":"The clinical importance of drug interactions with antiulcer therapy","volume":"12","author":"Reynolds","year":"1990","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","article-title":"Acid-suppressive medications and risk of bone loss and fracture in older adults","volume":"83","author":"Yu","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.gtc.2010.08.009_bib57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/bega.2001.0190","article-title":"Problems related to acid rebound and tachyphylaxis","volume":"15","author":"Gillen","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib58","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/EDE.0b013e3181b5f27d","article-title":"Acid-suppressive drugs and community-acquired pneumonia","volume":"20","author":"Rodr\u00edguez","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.gtc.2010.08.009_bib59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00002018-200124010-00004","article-title":"Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists","volume":"24","author":"Fisher","year":"2001","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.gtc.2010.08.009_bib60","doi-asserted-by":"crossref","first-page":"803","DOI":"10.7326\/0003-4819-105-5-803_1","article-title":"H2-antagonists and hepatitis","volume":"105","author":"Dobbs","year":"1986","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.gtc.2010.08.009_bib61","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/BF02088230","article-title":"Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study","volume":"41","author":"Magee","year":"1996","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.gtc.2010.08.009_bib62","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/oxfordjournals.aje.a010036","article-title":"Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes","volume":"150","author":"Ruigomez","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.gtc.2010.08.009_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/00365529109093218","article-title":"Sucralfate\u2013safety and side effects","volume":"185","author":"Marks","year":"1991","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"8","key":"10.1016\/j.gtc.2010.08.009_bib64","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/00365529109037018","article-title":"Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward","volume":"26","author":"Estruch","year":"1991","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gtc.2010.08.009_bib65","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0272-6386(88)80099-4","article-title":"Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder","volume":"12","author":"Malberti","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.gtc.2010.08.009_bib66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome\u2013results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2010.08.009_bib67","unstructured":"Dicyclomine [package insert]. Birmingham, AL: Axcan Pharma US Inc; 2008."},{"key":"10.1016\/j.gtc.2010.08.009_bib68","unstructured":"Hyoscyamine sulfate [package insert]. St. Louis, MO: Ethex Corporation; 2006."},{"key":"10.1016\/j.gtc.2010.08.009_bib69","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archfami.8.3.243","article-title":"Loperamide-simethicone vs loperamide alone, simethicone alone, and placebo in the treatment of acute diarrhea with gas-related abdominal discomfort. A randomized controlled trial","volume":"8","author":"Kaplan","year":"1999","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.gtc.2010.08.009_bib70","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/000992289903801003","article-title":"A\u00a0multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children","volume":"38","author":"Kaplan","year":"1999","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.gtc.2010.08.009_bib71","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/13543784.9.1.147","article-title":"Pharmacology and clinical experience with alosetron","volume":"9","author":"Camilleri","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.gtc.2010.08.009_bib72","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1517\/14656566.4.11.2089","article-title":"Alosetron and irritable bowel syndrome","volume":"4","author":"Mayer","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.gtc.2010.08.009_bib73","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1572-0241.2003.07418.x","article-title":"Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride","volume":"98","author":"Miller","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00002018-200427050-00001","article-title":"Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?","volume":"27","author":"Andresen","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.gtc.2010.08.009_bib75","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib76","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2004.09.055","article-title":"American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis","volume":"127","author":"Parkman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2010.08.009_bib77","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archinte.1993.00410120051007","article-title":"The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders","volume":"153","author":"Ganzini","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gtc.2010.08.009_bib78","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/j.1572-0241.2007.01255.x","article-title":"Domperidone: review of pharmacology and clinical applications in gastroenterology","volume":"102","author":"Reddymasu","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2010.08.009_bib79","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2036.2010.04265.x","article-title":"Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study","volume":"31","author":"Lembo","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2010.08.009_bib80","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1074248409340158","article-title":"Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study","volume":"14","author":"Anderson","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.gtc.2010.08.009_bib81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10620-009-1049-0","article-title":"Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies","volume":"55","author":"Chey","year":"2010","journal-title":"Dig Dis Sci"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855310000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855310000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T13:15:33Z","timestamp":1711890933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855310000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0889855310000518"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2010.08.009","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}